EXAM 4 antivirals 1 HSV, VZV, CMV, FLU Flashcards

1
Q

Herpes simplex viruses 1 (HSV1)

A

oral herpes
diagnosis via swab and PCR testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Herpes simplex viruses 2 (HSV2)

A

Genital mucosa
Commonly causes genital herpes
Infection within sacral ganglia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HSV1 + HSV2

A

central nervous system

HSV encephalitis is mostly caused by HSV1

Can see changes on imaging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

anti-herpes agents

A

Acyclovir
Valacyclovir
Famciclovir (not used in practice)
Penciclovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

acyclovir MOA

A

Prodrug that gets requires 3 step phosphorylation

Virus produces enzyme that causes selective phosphorylation

competitive inhibitor of viral DNA polymerase and competes with dGTP (guanine).

Acts as a chain terminator and inhibits DNA synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

acyclovir spectrum

A

active against HSV-1, HSV-2, and VZV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

acyclovir resistance

A

Two mechanisms: mutations in thymidine kinase and DNA polymerase

More likely to occur in immunocompromised people

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

acyclovir adverse effects

A

Nephrotoxicity: more likely to occur with IV admin

Give w/ IV fluids to prevent

but generally well tolerated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

valacyclovir

A

L-valyl ester of acyclovir and is converted to acyclovir by esterase in intestine and liver

improved efficacy compared to acyclovir (increased oral bioavailability)

SAME ADRs, MOA, and spectrum as acyclovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

famciclovir and penciclovir MOA

A

competitive inhibitor of viral DNA polymerase

Does not cause immediate chain termination

Obligate DNA chain terminator (incorporate into DNA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

famciclovir and penciclovir resistance

A

Viral kinase mutants: confer cross-resistance to penciclovir and acyclovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

famciclovir vs penciclovir

A

famiclovir is a prodrug of penciclovir

famciclovir is converted by first pass metabolism in intestine and liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

penciclovir vs acyclovir

A

higher affinity for HSV TK than acyclovir because it is more stable

HSV DNA polymerase have higher affinity for acyclovir triphosphate than penciclovir triphosphate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Varicella Zoster virus

A

DNA virus that cases infections referred to chickenpox or shingles

Varicella (chicken pox)

Zoster (shingles)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Varicella Zoster virus treatment

A

acyclovir

valacyclovir
oral for varicella or zoster
IV for disseminated zoster

famciclovir
used to treat zoster

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Cytomegalovirus

A

Severe infection can occur if during fetal development or in immunocompromised patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Cytomegalovirus drug therapy

A

ganciclovir
valganciclovir

18
Q

ganciclovir and valganciclovir MOA

A

same as penciclovir

competitive inhibitor of viral DNA polymerase

Does not cause immediate chain termination

Obligate DNA chain terminator (incorporate into DNA)

19
Q

ganciclovir vs acyclovir

A

better substrate for CMV than acyclovir

20
Q

ganciclovir ADRS

A

bone marrow suppression
main side effect –> dose limiting

21
Q

ganciclovir resistance

A

due to mutations in CMV kinase (UL97) or CMV DNA pol (UL54)

mutations in kinase are not cross-resistant to cidofovir or foscarnet

mutations in DNA pol may be cross-resistant to cidofovir or foscarnet

22
Q

valganciclovir

A

Monovalyl ester of ganciclovir (increases oral bioavailability 60%)

Rapidly hydrolyzed to ganciclovir

Uses: treat CMV retinitis

23
Q

foscarnet MOA

A

inhibits viral DNA polymerase

Does not require phosphorylation for activity

Carboxyl overlaps with binding site of phosphonates and traps polymerase in closed formation

24
Q

foscarnet spectrum

A

CMV retinitis

25
foscarnet resistance
mutations in DNA pol or HIV RT Resistant CMV isolates are cross resistant to ganciclovir Foscarnet is usually still effective against cidofovir resistant CMV
26
Cidofovir MOA
competitive inhibitor and chain terminator Does not require activation by viral kinases
27
Cidofovir spectrum
CMV HSV1/2 VZV adenovirus poxvirus polymavirus HPV
28
Letermovir MOA
inhibits terminase complex (responsible for cutting out genomes during DNA replication process): pUL56/89/51 Result: inhibition of CMV replication and prevention of CMV infection
29
letermovir drug interactions
CYP3A4 inhibitor, substrate/inhibitor of OATP1B1/3
30
life cycle of influenza virus
Virus is sysnthesized within the cell which undergoes mRNA synthesis and RNA replication The mature cell is connected to the outside of the host cell Neuraminidase cleaves this connection (glycolytic bonds) and frees the virus cell This facilitates virus dissemination: hemataglutin binds to terminal sialic acid residues
31
target for influenza virus
Neuraminidase: is the main target Neuraminidase inhibitors block this cleavage Essential for virus replication
32
drugs to treat influenza virus
oseltamivir zanamivir permivir baloxavir marboxil
33
oseltamivir and zanamivir MOA
Prodrug converted to active form by liver Metabolite is an effective inhibitor of NA
34
oseltamivir and zanamivir spectrum
active against influenza A and B
35
oseltamivir and zanamivir resistance
mutations in active site of neuraminidase There is flu A virus with reduced susceptibility to oseltamivir Drug resistant virus occurs in 3% of patients receiving oseltamivir More resistance against oseltamivir compared to zanamivir
36
peramivir MOA
Parental NA inhibitor
37
peramivir spectrum
effective against influenza A and B
38
peramivir resistance
mutation in active site of neuraminidase
39
Baloxavir marboxil MOA
inhibits viral “cap-snatching” --> blocks transcription Binds to PB2 subunit of RNA pol and inhibits cap-dependent endonuclease
40
Baloxavir marboxil spectrum
flu within first 48 hrs of symptoms